12-01 :: January 2012
on of VelQuest extends Accelrys‘ software portfolio into the downstream pharmaceutical development Quality Assurance and Quality Control (QA/QC) space, offering significant productivity improvements, faster cycle times, lower operational costs and re- duced compliance risks for regulated life sciences organizations.
and registration of insulins, including analogue insulins. Within the framework of the joint-venture, Bioton will be responsible for the development and manufacture of insulin products, while Actavis will be granted an exclusive licence to commercialise those products under the Actavis brand throughout the European Union and the United States of America, as well as in Albania, Bosnia & Herzegovina, Croatia, Iceland, Japan, Kosovo, Lichtenstein, Macedonia, Montenegro, Norway, Serbia and Switzerland.
1-for-10 reverse stock split of the Company’s com- mon stock at its Special Meeting of Stockholders held today.
cusphere, Inc. (ACUS.PK) announced that its stockholders voted to approve the proposed
ctavis and Bioton (WSE:BIO) have formed a joint venture company for the development
Research and Development Agreement (CRADA) with the US Air Force Research Laboratory (AFRL), Materials and Manufacturing Directorate, Airbase Technologies Division, Tyndall AFB, Florida to continue to develop and commercialize the paten- ted and award winning Reactive Surface Treatment (RST) technology. This collaboration is a joint effort that will explore the RST technology on a variety of materials, integrate nanoparticles developed by the Air Force in various RST treatment applications, and demonstrate a commercially feasible and scalable production process. The outcome of this activity is anticipated to result in greater soldier protection from chemical and biological threats and improved materials used in military and commercial applica- tions.
Moreover, Alexium International has commenced trading on the OTC markets prestigious tier, OTCQX International. The quotation is now active on the OTCQX website and can be found by searching un- der Alexium code of AXXIY.
Alexium also announced it is forging ahead with Bruck Textiles on several joint development projects and license negotiations for the Australasia region. While the product developments and negotiations are covering a broader spectrum of fabrics, Alexium and Bruck are already engaged in performance trials for ballistic fabrics treated with Alexium’s repellency treatment. Importantly, Alexium’s RST repellency treatments do not contain perfluorooctanoic acids (PFOAs) or perfluorooctanesulfonic acids (PFOSs), which are currently used by other traditional repel- lency treatments, and which are now being phased
lexium International Group Limited (ASX:AJX, OTC QX:AXXIY) has signed a new Cooperative